Piper Sandler Reiterates Overweight on Orchestra BioMed Hldgs, Raises Price Target to $10
Piper Sandler analyst Matt O'Brien reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $9 to $10.
Stocks · News reference
Orchestra BioMed Hldgs Q2 EPS $(0.38) Misses $(0.37) Estimate, Sales $88.000K Miss $121.400K Estimate
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.37) by 2.7 percent. This is a 24 percent increase over losses of $(0.50) per share
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced its inclusion in the Russell 3000 Index and Russell 2000 Index following the 2026 Russell indexes reconstitution effective June 26, 2026. The biomedical company develops AVIM Therapy for hypertension in collaboration with Medtronic and Virtue SAB for atherosclerotic artery disease, both undergoing pivotal clinical trials.
Orchestra BioMed Included In Russell 3000 And Russell 2000 Indexes